New items support animals’ psychological health and allergic actions, struck market in Taiwan following effective launch of VELDONA® Pet
Expanding VELDONA® Pet line of product develops development momentum towards US$20M sales target for 2024
SAN DIEGO, CA / ACCESSWIRE / June 7, 2023 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) (“Ainos”, or the “Company”), a varied medtech business concentrated on the advancement of unique point-of-care screening, low-dose interferon therapies, and artificial RNA-driven preventative medication, today revealed the launch of 2 brand-new additions to its VELDONA® Pet cytoprotein supplement line of product. VELDONA® Pet Lohas, developed to support animals’ psychological health and alleviate tension, and VELDONA® Pet Soothing, created to alleviate pain brought on by allergic reactions, will be released in Taiwan in July. Ainos goes for US$20 million in sales from its VELDONA® Pet supplements throughout 2024, with extra item releases and growth of sales and marketing in other areas.
VELDONA® Pet Lohas adds to the psychological wellness of dogs and cats, supplying remedy for tension and pain. A research study performed by China Medical University showed that interferon treatments might minimize the threat of anxiety by helping in the guideline of cellular inflammatory actions in the brain. Interferon might likewise favorably impact the regrowth and improvement of synapses in between afferent neuron in the brain.
VELDONA® Pet Soothing stabilizes a family pet’s immune action to irritants by causing the body’s natural guideline system. The item is developed to minimize pain and milder allergic signs. The efficiency of interferons in controling allergies has actually been discovered in a research study performed by the National Research Institute of Japan.
Both supplements will be marketed in Taiwan starting next month. Their launch follows carefully on the heels of recently’s release of Ainos’ VELDONA® Pet cytoprotein health supplement, which is presently available to family pet owners in Taiwan. Ainos prepares to present its portfolio of family pet items to extra markets in the future as part of its international business advancement method.
Chun-Hsien Tsai, Ainos’ Chairman of the Board, President, and Chief Executive Officer, commented, “The release of our latest VELDONA® Pet supplements is an essential turning point in this genuinely transformational year for Ainos. Diversifying our item portfolio makes our business more powerful and leads the way for our future development and advancement. With each brand-new launch, we are offering family pet owners extra choices to guarantee the health of their buddies and placing ourselves to record a financially rewarding share of the growing family pet health market.”
“With our progressively robust item portfolio and the prepared intro of our present offerings to markets around the globe, we are building an outstanding structure for our target of US$20 million in sales of our VELDONA® Pet supplements in 2024,” Mr. Tsai included. “The 2nd half of 2023 will be an exhilarating time for Ainos as we continue to work relentlessly towards this objective. I am extremely pleased with our group’s drive and execution as we non-stop pursue the development of our business.”
About VELDONA® Pet
Based on Ainos’ low-dose oral interferon-alpha (“IFNα”) solution, VELDONA® Pet cytoprotein supplements are backed by many research study studies and medical trials, and are produced with first-rate products in an extremely licensed food-grade plant. VELDONA® keeps resistance and adds to gum and skin health, eliminating allergic reactions and decreasing tension in cats and dogs. Interferon, a kind of cytoprotein, is naturally produced by human and animals. When cells are attacked by foreign particles, immune signaling particles alert surrounding cells. Once nearby cells receive the interferon’s protein signal through their surface area receptors, they start and regulate the body immune system to secure felines and dogs from gum and skin illness, allergic reactions, and stress-related conditions.
A medical research study, sponsored by Ainos and performed by the Agricultural Technology Research Institute in Taiwan, has actually shown that VELDONA® assists preserve the body immune systems of cats and dogs. Numerous research studies have actually reported the advantages of interferons in keeping gum health and skin health, eliminating pain brought on by allergic reactions, and calming psychological tension in cats and dogs. VELDONA® Pet’s objective is to preserve resistance for countless animals with the first-rate items.
About Ainos, Inc.
Headquartered in San Diego, California, Ainos, Inc. is a varied medtech business participated in establishing ingenious medical innovations for point-of-care screening and safe and unique medical treatment for a broad variety of illness indicators. In addition to its exclusive therapies utilizing low-dose non-injectable interferon, Ainos has actually likewise broadened its item portfolio to consist of Volatile Organic Compounds (VOC) and COVID-19 POCTs. Powered by its AI Nose platform, the lead POCT prospect, Ainos Flora, is a telehealth-friendly POCT for ladies’s health and specific typical STIs. To learn more, check out https://www.ainos.com.
Follow Ainos on Twitter (@AinosInc) and LinkedIn to remain updated.
Forward-Looking Statements
This news release consists of “positive declarations” about Ainos within the significance of the safe harbor arrangements of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking declarations can be determined by the usage of words such as “expect,” “think,” “quote,” “anticipate,” “mean,” “strategy,” “anticipate,” “job,” “target,” “future,” “likely,” “method,” “predict,” “may,” “assistance,” “possible,” “outlook,” “projection,” “should,” “will” or other comparable words or expressions. Similarly, declarations that explain the Company’s goals, strategies or objectives are, or might be, positive declarations. Forward-looking declarations are based just on the Company’s present beliefs, expectations, and presumptions. Forward-looking declarations undergo fundamental unpredictabilities, dangers, and modifications in scenarios that are tough to anticipate and much of which are beyond the Company’s control. The Company’s real outcomes might vary materially from those shown in the positive declarations.
Important aspects that might trigger the Company’s real outcomes to vary materially from the forecasts, projections, price quotes and expectations talked about in this news release consist of, to name a few, the cost of production and sales capacity of the prepared drug treatments revealed in this news release; the Company’s reliance on earnings from the sale of COVID-19 test sets; the Company’s restricted money and history of losses; the Company’s capability to accomplish success; the Company’s capability to raise extra capital to continue the Company’s item advancement; the capability to properly anticipate the future operating outcomes of the Company; the capability to advance Ainos’ present or future item prospects through medical trials, obtain marketing approval and eventually advertise any item prospects the Company establishes; the capability to obtain and preserve regulative approval of Ainos item prospects; hold-ups in finishing the advancement and commercialization of the Company’s present and future item prospects, which might lead to increased expenses to the Company, hold-up or restrict the capability to produce profits and negatively impact the business, monetary condition, outcomes of operations and potential customers of the Company; extreme competitors and quickly advancing innovation in the Company’s market that might exceed its innovation; client need for the product or services the Company establishes; the effect of competitive or alternative items, innovations and prices; interruption in research study and advancement centers; claims and other claims by 3rd parties or examinations by numerous regulative companies governing the Company’s operations; possible cybersecurity attacks; increased requirements and expenses connected to cybersecurity; the Company’s capability to understand the advantages of 3rd party licensing arrangements; the Company’s capability to obtain and preserve copyright security for Ainos item prospects; compliance with relevant laws, policies and tariffs; and the Company’s success in handling the development. A more total description of these threat aspects and others is consisted of in the “Risk Factors” area of Ainos’ most recent Annual Report on Form 10-K and other reports submitted with the U.S. Securities and Exchange Commission, much of which dangers are beyond the Company’s control. In addition to the dangers explained above and in the Company’s Form 10-K, other unidentified or unforeseeable aspects likewise might trigger real outcomes to vary materially from the forecasts, projections, price quotes and expectations talked about in this news release.
The positive declarations made in this news release are specifically certified in their totality by the foregoing cautionary declarations. Ainos carries out no responsibility to, and specifically disclaims any such responsibility to, openly update or modify any positive declaration to show altered presumptions, the event of expected or unexpected occasions or modifications to the future outcomes gradually or otherwise, other than as needed by law.
Investor Relations Contact
ICR, LLC
Robin Yang
Tel: +1 646-224-6971
Email: [email protected]
SOURCE: Ainos, Inc.
